Humana stock rose 4.68 percent after Barclays raised its target

Published on 09/28/2026 at 14:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Humana stock last stood at USD 398.13 on September 25, 2026, after Barclays raised its target from USD 407.00 to USD 515.00. Q2 EPS reached USD 7.61 against USD 7.27 consensus.

HUM, US4456581077, Illustration mit AI erstellt.

Humana Inc. (ISIN US4456581077) was last at USD 398.13 on the New York Stock Exchange on September 25, 2026 at 3:59 p.m. ET, up 4.68 percent from the prior close of USD 380.32. The immediate catalyst was Barclays, which upgraded the insurer to Overweight and lifted its price target from USD 407.00 to USD 515.00.

Barclays raises the valuation bar

According to Investing.com on September 25, 2026, Barclays analyst Andrew Mok changed the rating from Equal Weight to Overweight and raised the target by USD 108.00. The new target stands 29.36 percent above the USD 398.13 reference price, using the target and last traded price from the same snapshot.

The upgrade centered on Humana's Medicare Advantage outlook and the probability of improvement in CMS Star Ratings. Investing.com reported that Barclays placed the probability of an upgrade for Humana's H5216 contract at 75 percent.

Q2 earnings beat expectations

Humana's operating backdrop also improved in the second quarter. MarketBeat reported diluted EPS of USD 7.61 for the quarter ended June 30, 2026, versus USD 7.27 consensus. Revenue reached USD 40.89 billion, up 26.2 percent year over year and above the USD 40.58 billion estimate.

The comparison matters because the earnings beat and revenue growth give the Barclays call an operating anchor rather than leaving the rerating dependent only on future Medicare Advantage quality scores. MarketBeat also reported a 52-week range of USD 163.11 to USD 428.88, leaving the September 25 price 7.17 percent below the high.

Guidance points to USD 9.00 adjusted EPS

In its Form 8-K dated September 1, 2026, the SEC filing said Humana intended to reaffirm FY 2026 guidance of at least USD 6.52 in diluted GAAP EPS and at least USD 9.00 in adjusted EPS. The filing also said final 2027 Medicare Advantage Star Ratings data are expected from CMS in October, making that release the next major test for the recovery narrative.

Humana stock remains below its yearly high

Humana stock was last at USD 398.13 on the NYSE on September 25, 2026 at 3:59 p.m. ET, with volume of 1,933,321 shares and market capitalization of USD 47.8 billion. The stock's 52-week range was USD 163.11 to USD 428.88.